Organization · Grant Maker
T1D Fund
The T1D Fund is a not-for-profit organization based in Boston, Massachusetts, focused on accelerating treatments and cures for Type 1 Diabetes (T1D). It operates as a venture philanthropy fund, investing in companies developing disease-modifying therapies for T1D.
Overview
What T1D Fund does
What T1D Fund is
The T1D Fund is a not-for-profit organization based in Boston, Massachusetts, focused on accelerating treatments and cures for Type 1 Diabetes (T1D). It operates as a venture philanthropy fund, investing in companies developing disease-modifying therapies for T1D.
How it participates in the startup ecosystem
The current public profile supports funder and grantor capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Grant Maker
- Founded
- Founded in 2016
- Approximate age
- About 10 years
- Structured capabilities
- Funder · Grantor
- Last reviewed
- March 5, 2026
Official channels
Find T1D Fund elsewhere
Open the official website or a supported primary organization account.
Capability profile
T1D Fund as a funder
Investment thesis
The T1D Fund invests in companies developing disease-modifying therapies and cures for Type 1 Diabetes. Its strategy is modality agnostic, targeting a variety of therapeutic approaches across different stages of development.
Focus narrative
The T1D Fund invests in companies developing disease-modifying therapies and cures for T1D. Its investment strategy is modality agnostic, targeting a wide range of therapeutic approaches, including autoimmune and regeneration, cell replacement, and metabolic control. The fund seeks to support differentiated, curative potential treatments across various stages of development, from discovery to clinical assets. Geographically, the T1D Fund's investments span the globe, reflecting a belief that innovation knows no boundaries.
Focus and fit
- Stages
- Pre-seed · Seed · Seed+ · Series A · Series B · Series C
- Regions
- Global
Availability
- Currently deploying
- Not published
Portfolio and track record
- Recorded portfolio count
- 25
Portfolio context
The T1D Fund's portfolio includes notable companies such as AnTolRx, Inc., developing antigen-specific immune tolerance therapies; AltruBio, targeting T cell mediated autoimmune diseases; Bigfoot Biomedical, creating a diabetes management ecosystem; Biolinq, developing a biosensor patch; Capillary Biomedical, innovating insulin infusion set technology; COUR Pharmaceuticals, delivering disease-specific antigens; Diasome Pharmaceuticals, focusing on liver-targeted insulin; eGenesis Bio, working on renewable islet sources; Kriya Therapeutics, utilizing gene therapy for insulin independence; and ImmusanT, developing peptide desensitization therapy.
Capability profile
T1D Fund as a grantor
Grant thesis
The T1D Fund is dedicated to accelerating treatments, prevention, and cures for Type 1 Diabetes (T1D) through strategic investments in innovative companies.
Focus narrative
The T1D Fund invests in companies developing disease-modifying therapies and cures for Type 1 Diabetes. Its investment strategy is modality agnostic, targeting a wide range of therapeutic approaches, including autoimmune and regeneration, cell replacement, and metabolic control. The fund supports differentiated, curative potential treatments across various stages of development, from discovery to clinical assets.
Value and support
Beyond funding, the T1D Fund leverages investment banking, pharmaceutical, and business development expertise to catalyze innovation in T1D therapies, providing strategic support to its portfolio companies.
Grant economics
- Dilutive
- No
- Nonprofit only
- Yes
Availability
- Application state
- Accepting
Eligibility and fit
- Stages
- Pre-seed · Seed · Seed+ · Series A · Series A+ · Series B · Series B+ · Series C · Series C+ · Series D · Series E · Series F · Growth Equity
- Audience
- Founders
- Regions
- Global
Process and recipient context
Application process
For more information or to apply for funding, interested parties can visit the T1D Fund's website. The application process details are available there, guiding applicants on how to submit their proposals effectively.
Recipient context
The T1D Fund's portfolio includes notable companies such as AnTolRx, Inc., AltruBio, Bigfoot Biomedical, Biolinq, Capillary Biomedical, COUR Pharmaceuticals, Diasome Pharmaceuticals, eGenesis Bio, Kriya Therapeutics, and ImmusanT, all working on innovative solutions for Type 1 Diabetes.
Common questions
What to know about T1D Fund
Upseed classifies T1D Fund under the Grant Maker organization type. Its current public profile includes funder and grantor capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 5, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.